محطة عمل مربحة للمختبرات الطبية - تيبيريوس

معلومات اساسية

• متاح على:
• English
• العربية

The EarlyTect Colon Cancer Test is a highly reliable and effective tool in the early detection of colorectal cancer. It has been rigorously tested and approved by the Korea Ministry of Food and Drug Safety, following clinical trials conducted at prestigious medical institutions such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center.

This test utilizes a qualitative real-time PCR method to measure the presence of methylated Syndecan-2, a biomarker that is clinically associated with precancerous lesions of colorectal cancer, in stool DNA. Through these clinical trials, it has been demonstrated that the EarlyTect Colon Cancer Test boasts an impressive sensitivity and specificity of 90% in diagnosing colorectal cancer.

It is important to note that this product is not intended to confirm the presence of colorectal cancer. Rather, a positive result indicates the potential existence of colorectal cancer or precancerous lesions of colorectal cancer. Therefore, further medical evaluation and diagnostic procedures should be pursued if a positive result is obtained.

The product adheres to strict standards and specifications. It is specifically designed for colorectal cancer screening in asymptomatic individuals. The biomarker used in this test is SDC2 me.

For pricing and transaction details, please contact us directly. We are open to negotiation and can provide a personalized quote based on your specific requirements.